Progress of exosomes in diagnosis and treatment of prostate cancer

doi:10.16352/j.issn.1001-6325.2022.01.026

Abstract

Abstract: Prostate cancer(PCa) is a common malignancy in males. Exosomes are lipid bilayer vesicles containing protein, mRNA and miRNA, which are active in intercellular communications. Exosomes promotes the development of prostate cancer, support immune evading and chemotherapy resistance, stimulate angiogenesis, induce epithelial-mesenchymal transition(EMT) of tumor cells, and contribute to the formation of pre-metastasis niche, thus promoting the invasion and metastasis of prostate cancer. Based on the role in tumor biological behavior and heterogeneity in different cells, exosomes hold great potentials as biomarker for diagnosis and prognosis of prostate cancer, and are expected to become a favorable drug carrier. It has a promising prospect for cancer therapy.

Key words: prostate cancer, exosomes, biomarkers, tumor

CLC Number:

R737.25

LI Ying-jie, YANG Ting-kai, JI Zhi-gang, WEN Jin. Progress of exosomes in diagnosis and treatment of prostate cancer[J]. Basic & Clinical Medicine, 2022, 42(1): 163-167.

References

[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424.
[2]Saini S. PSA and beyond: alternative prostate cancer biomarkers[J]. Cell Oncol (Dordr), 2016, 39: 97-106.
[3]Cocozza F, Grisard E, Martin-Jaular L, et al. Snapshot: extracellular vesicles[J]. Cell, 2020, 182: 262-262.e1. doi: 10.1016/j.cell.2020.04.054.
[4]Albino D, Falcione M, Uboldi V, et al. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer[J]. Commun Biol, 2021, 4: 119. doi:10.1038/s42003-020-01642-5.
[5]Dai Y, Gao X. Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1[J]. Cancer Cell Int, 2021, 21: 145. doi:10.1186/s12935-020-01686-x.
[6]Herrera M, Llorens C, Rodríguez M, et al. Differential distribution and enrichment of non-coding RNAs in exosomes from normal and cancer-associated fibroblasts in colorectal cancer[J]. Mol Cancer, 2018, 17: 114. doi: 10.1186/s12943-018-0863-4.
[7]Wu M, Wang G, Hu W, et al. Emerging roles and therapeutic value of exosomes in cancer metastasis[J]. Mol Cancer, 2019, 18: 53. doi: 10.1186/s12943-019-0964-8.
[8]Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer meta-stasis and drug resistance[J]. Mol Cancer, 2019, 18: 75. doi: 10.1186/s12943-019-0991-5.
[9]Lorenc T, Klimczyk K, Michalczewska I, et al. Exosomes in prostate cancer diagnosis, prognosis and therapy[J]. Int J Mol Sci, 2020, 21: 2118. doi:10.3390/ijms21062118.
[10]Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560: 382-386.
[11]Sinha D, Roy S, Saha P, et al. Trends in research on exosomes in cancer progression and anticancer therapy[J]. Cancers, 2021, 13: 326. doi:10.3390/cancers13020326.
[12]Li Y, Li Q, Li D, et al. Exosome carrying PSGR promotes stemness and epithelial-mesenchymal transition of low aggressive prostate cancer cells[J]. Life Sci, 2021, 264: 118638. doi:10.1016/j.lfs.2020.118638.
[13]Guo Y, Ji X, Liu J, et al. Effects of exosomes on pre-metastatic niche formation in tumors[J]. Mol Cancer, 2019, 18: 39. doi:10.1186/s12943-019-0995-1.
[14]Akoto T, Saini S. Role of exosomes in prostate cancer metastasis[J]. Int J Mol Sci, 2021, 22: 3528. doi:10.3390/ijms22073528.
[15]Yu L, Sui B, Fan W, et al. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p[J]. J Extracell Vesicles, 2021, 10: e12056. doi:10.1002/jev2.12056.
[16]Borel M, Lollo G, Magne D, et al. Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866: 165919. doi:10.1016/j.bbadis.2020.165919.
[17]Zhang Y, Chen B, Xu N, et al. Exosomes promote the transition of androgen-dependent prostate cancer cells into androgen-independent manner through up-regulating the heme oxygenase-1[J]. Int J Nanomedicine, 2021, 16: 315-327.
[18]Zhang Y, Zhao J, Ding M, et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis[J]. J Exp Clin Cancer Res, 2020, 39: 282. doi:10.1186/s13046-020-01761-1.
[19]Shan G, Gu J, Zhou D, et al. Cancer-associated fibroblast-secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β signaling pathway[J]. Exp Mol Med, 2020, 52: 1809-1822.
[20]Duca RB, Massillo C, Dalton GN, et al. miR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis[J]. Am J Cancer Res, 2021, 11: 2802-2820.
[21]Ji J, Chen R, Zhao L, et al. Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer[J]. Mol Cancer, 2021, 20: 58. doi:10.1186/s12943-021-01349-z.
[22]Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer[J]. Eur Urol, 2015, 67: 33-41.
[23]Guo T, Wang Y, Jia J, et al. The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing[J]. Front Cell Dev Biol, 2020, 8: 602493. doi:10.3389/fcell.2020.602493.
[24]Shin S, Park YH, Jung SH, et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J]. NPJ Genom Med, 2021, 6: 45. doi:10.1038/s41525-021-00212-w.
[25]Krishn SR, Singh A, Bowler N, et al. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes[J]. Matrix Biol, 2019, 77: 41-57.
[26]Del Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide[J]. Prostate Cancer Prostatic Dis, 2021, 24: 524-531.
[27]Severic M, Ma G, Pereira SGT, et al. Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo[J]. J Control Release, 2021, 330: 101-110.
[28]Gaballa R, Ali HEA, Mahmoud MO, et al. Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchy-mal transition[J]. Cancers (Basel), 2020, 12: 2300. doi:10.3390/cancers12082300.
[29]Han Q, Xie QR, Li F, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer[J]. Theranostics, 2021, 11: 6526-6541.
[30]Xu Z, Zeng S, Gong Z, et al. Exosome-based immunotherapy: a promising approach for cancer treatment[J]. Mol Cancer, 2020, 19: 160. doi:10.1186/s12943-020-01278-3.
[31]Morishita M, Takahashi Y, Matsumoto A, et al. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA[J]. Biomaterials, 2016, 111: 55-65.
[32]Kim J, Shim JS, Han BH, et al. Hydrogel-based hybridization chain reaction (HCR) for detection of urinary exosomal miRNAs as a diagnostic tool of prostate cancer[J]. Biosens Bioelectron, 2021, 192: 113504. doi:10.1016/j.bios.2021.113504.